These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Resolution: RU 486. American Association for the Advancement of Science Science; 1991 Apr; 252(5005):587. PubMed ID: 11642875 [No Abstract] [Full Text] [Related]
4. Does genetic engineering need genetic engineers?: should the regulation of genetic engineering include a new professional discipline? Auchincloss S Boston Coll Environ Aff Law Rev; 1993; 20(1):37-63. PubMed ID: 11652234 [No Abstract] [Full Text] [Related]
5. Regulation of genetic modification of organisms: science or emotion? Malinowski MJ J Biolaw Bus; 1998; 1(3):3-7. PubMed ID: 11657280 [No Abstract] [Full Text] [Related]
6. Laetrile: the battle moves into the courtroom. Schwartz RL Am Bar Assoc J; 1979 Feb; 65():224-8. PubMed ID: 11661617 [No Abstract] [Full Text] [Related]
8. Perspectives on the FDA status of drug products manufactured by the recombinant DNA technique. Korwek EL; Trinker DS Food Drug Cosmet Law J; 1981 Oct; 36(10):517-35. PubMed ID: 11650658 [No Abstract] [Full Text] [Related]
9. Implications of the federal drug investigation and approval processes for the development and availability of AIDS treatments and vaccines. Mathers PR AIDS Public Policy J; 1987; 2(2):50-3. PubMed ID: 11650030 [No Abstract] [Full Text] [Related]
10. Rules to protect drug-test participants via follow-up exams are slated by FDA. Spivak J Wall St J (East Ed); 1976 Mar; ():5. PubMed ID: 11649042 [No Abstract] [Full Text] [Related]
11. RU 486 and the politics of drug regulation in the United States and France. Kramnick RK Cornell Int Law J; 1992; 25():667-718. PubMed ID: 11656340 [No Abstract] [Full Text] [Related]
12. Ethics lobby forces rethink on growth hormones. Miller SK New Sci; 1992 Aug; 135(1834):9. PubMed ID: 11659508 [No Abstract] [Full Text] [Related]
13. Drug firm was aware of deaths, probe says. Mintz M Washington Post; 1982 Dec; ():A2. PubMed ID: 11647760 [No Abstract] [Full Text] [Related]
14. FDA treatment use regulations: a compassionate response. Weitzman SA; Marcy T AIDS Public Policy J; 1987; 2(2):22-32. PubMed ID: 11650028 [No Abstract] [Full Text] [Related]
15. Regulating genetic engineering in an era of increased judicial deference: a proper balance of the federal powers. Von Oehsen WH Adm Law Rev; 1988; 40(3):303-44. PubMed ID: 11650827 [No Abstract] [Full Text] [Related]
16. The judicial dilemma of Laetrile and a possible solution. Pendergast WR Mercer Law Rev; 1979; 30(3):573-84. PubMed ID: 11661827 [No Abstract] [Full Text] [Related]
17. Firm allegedly sold vitamin after it learned of deaths. Russell C Washington Post; 1984 May; ():A1, A19. PubMed ID: 11646393 [No Abstract] [Full Text] [Related]
18. Why Laetrile won't go away. Edson L N Y Times Mag; 1977 p 41+; 27 Nov 1977():. PubMed ID: 11662576 [No Abstract] [Full Text] [Related]
19. Military medical research: 2. Proving the safety and effectiveness of a nerve gas antidote -- a legal view. Cooper RM IRB; 1989; 11(4):7-9. PubMed ID: 11650245 [No Abstract] [Full Text] [Related]
20. Recombinant DNA: a case study in regulation of scientific research. Chalfant JC; Hartmann ME; Blakeboro A Ecol Law Q; 1979; 8(1):55-129. PubMed ID: 11665069 [No Abstract] [Full Text] [Related] [Next] [New Search]